In addition, our study further demonstrated that ADM expression was positively associated with tumor mutational burden (TMB) and microsatellite instability (MSI) in several cancers, including COAD and TET, suggesting ADM’s potential as a biomarker for predicting the efficacy of immunotherapy. This evidence concerns the gene ADM and neoplasm.